• Drug: Yutrepia (treprostinil)
  • Manufacturer: Liquidia
  • Route of Administration: Inhalation
  • Site of Care: Outpatient

  • Approved Indication:

    • pulmonary arterial hypertension (WHO group 1) to improve exercise ability
    • pulmonary hypertension associated with interstitial lung disease (PH-ILD, WHO group 3) to improve exercise ability
  • Disease: pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD)

  • Therapeutic Area: Pulmonary

  • Enrollment Form Link: Enrollment Form
  • Phone Number: N/A
  • Fax Number: N/A

  • Product Website: yutrepia.com